This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Measles in pregnancy

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

  • there is no evidence to support an association between measles in pregnancy and congenital defects (1)

    • however, the need for effective post-exposure protection is supported by studies suggesting a high risk of severe maternal morbidity, fetal loss and prematurity
      • measles is more severe in pregnancy, and increases the risk of miscarriage, stillbirth, or preterm delivery (2)

    • measles in late pregnancy can also lead to perinatal infection in the infant, which may be associated with a high mortality and the risk of subacute sclerosing panencephalitis

    • UK guidance recommends using human normal immunoglobulin for susceptible pregnant women exposed to measles (1,2)
      • although there is no direct evidence that this will reduce the complications of measles in pregnancy, it may attenuate disease and therefore reduce the rate of complications
      • measures to identify women likely to be susceptible include assessment of age, vaccination history, and/or antibody testing
      • main aim of measles PEP (post exposure prophylaxis) for pregnant women is attenuation of disease and therefore human normal immunoglobulin (HNIG) can be used (2)
      • will be issued up to 6 days after exposure, allowing time for assessment of immunity status in most instances (2)
      • where a second exposure occurs more than 3 weeks after a first dose of immunoglobulin, a further dose may need to be considered (2)

Post exposure prophylaxis (PEP) with human normal immunoglobulin is recommended for neonates with recent in utero exposure, that is those born to mothers who develop a measles rash 6 days before to 6 days after delivery (2):

Pregnant women do not require post-exposure prophylaxis if they are inadvertently given MMR (2)

If considering an infectious cause for the development of the rash in pregnancy. A flowchart summarising contact with vesicular or non-vesicular rash (3):

Reference:


Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.